Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6728201 | 0.90 | KMT2A (0.40) | KMT2APOLBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL1156951 | 0.82 | CFB (0.33) | IDO1TDO2 | |
| SCHEMBL6728095 | 0.81 | POLB (0.44) | KMT2APOLBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL6727956 | 0.81 | KMT2A (0.41) | KMT2APOLBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL6728422 | 0.80 | POLB (0.40) | KMT2APOLBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL6727942 | 0.77 | POLB (0.48) | KMT2APOLBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL6728755 | 0.76 | KMT2A (0.43) | KMT2APOLBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL6728164 | 0.74 | KMT2A (0.43) | KMT2APOLBTAAR1ALDH1A1CYP2D6 | |
| SCHEMBL1157443 | 0.71 | CFB (0.36) | TAAR1IDO1TDO2 | |
| SCHEMBL12637686 | 0.71 | CFB (0.36) | TAAR1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183414-B2 | N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptors | ALLERGAN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183414-B2 | N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptors | ALLERGAN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| WO-2010077586-A1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-3H-PYRROL-2-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ALLERGAN, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100145061-A1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-2H-PYRROL-5-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ALLERGAN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100145061-A1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-2H-PYRROL-5-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ALLERGAN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145061-A1 | N-(1-PHENYL-2-ARYLETHYL)-4,5-DIHYDRO-2H-PYRROL-5-AMINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B OR ALPHA2B AND ALPHA2C ADRENOCEPTORS | ADRA2B, ADRB2, ADRA2C | KMT2A 2580/4885POLB 1602/4885TAAR1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.